Abstract:Abstract Background High density lipoprotein (HDL) exerts various atheroprotective functions including cholesterol efflux capacity (CEC). HDL can attenuate lipid burden at atherosclerotic lesion by CEC. Based on the HDL`s role for moderate atherosclerosis, HDL-cholesterol level which indicates the amount of HDL has been evaluated to assess the risk of cardiovascular disease (CVD). Nevertheless, many clinical studies demonstrated that HDL-cholesterol level does not always reflect the risk of CVD, and CEC which represents the quality of HDL is considered as surrogate biomarker for CVD. CEC is prospective biomarker for CVD risk assessment, however, CEC measurement encounters barriers for clinical application because of its requirements of cultured cell and radioactive substance for conventional CEC assay. To overcome these problems, we invented a novel CEC assay called immobilized liposome-bound gel beads (ILG) method. This method is cell-free assay and utilizes a fluorescence substance as cholesterol tracer. Although the ILG method is useful assay for clinical application, previous study revealed that bilirubin caused false positive error on CEC value. Hence, current ILG method might produce incorrect CEC evaluation for patients with hyperbilirubinemia and even healthy subjects within the range of biological variation of bilirubin. In this study, we improved the influence of bilirubin for ILG method by using bilirubin oxidase (BOD). Methods BOD (Asahi Kasei Corp.) was added to 10 mM Tris-HCl (pH 7.4) containing 150 mM of NaCl and 1 mM of Na2EDTA (Buffer A). Bilirubin from ‘Interference check A Plus’ (Sysmex Inc.) was added to serum (free-: 10 mg/dL, conjugated-:9.7 mg/dL), and apoB-depleted serum (BDS) was derived from the bilirubin additive serum using polyethylene glycol. After the prepared bilirubin additive BDS was incubated with BOD-containing Buffer A for 16 h, the absorbance spectrum was analyzed. In addition, the time course of bilirubin decrement was monitored during 16 h-incubation. We further measured the fluorescence intensity of bilirubin additive BDS incubated with BOD-containing Buffer A. Using the newly developed BOD-containing Buffer A for ILG method, CEC of bilirubin additive serum was evaluated. Finally, we measured CEC of 4 healthy individuals by conventional and the improved ILG method. The CEC value was standardized by fluorescence intensity of reference sample which was measured in every assay. Results BOD contained in Buffer A could convert bilirubin to biliverdin from results of absorbance spectrum. According to the time course of bilirubin decrement, both free- and conjugated-bilirubin were oxidized to biliverdin in approximately 6 h. By converting bilirubin to biliverdin, fluorescence light was weakened greatly. We confirmed that there was no significant difference of CEC values between non bilirubin-additive serum and bilirubin additive serum. Compared healthy individual CEC values measured by conventional and improved ILG method, all subjects showed significant decrease of CEC values from the improved method, and false positive error caused by bilirubin was ameliorated. Conclusion In this study, we achieved to improve the positive error caused by bilirubin on CEC assay using ILG method. This improvement would contribute to more accurate CEC assessment by ILG method and advance the clinical application of this method.

Observing Affection That CK and CK-MB Reagents Made in Measuring TG with Biochemical Automatic Analysis

A Rare Case of Falsely Elevated High-Sensitivity Cardiac Troponin T Due to Antibody Interference and a Literature Review

Effects of different specimen pretreatment methods on the measurement of thyrotropin stimulating hormone in serum

Hypertriglyceridemia Interferes with Hemoglobin Detection and Calibration Methods

Lab-On-A-Chip for Analysis of Triglycerides Based on A Replaceable Enzyme Carrier Using Magnetic Beads

Investigation of precision and trueness of results from the imported commercial systems for measurement of gamma-glutamyitransferase in serum

Attention should be paid to false-positive results due to heterophilic antibodies interfering with Abbott high-sensitivity cardiac troponin I assay

A-209 Application of Bilirubin Oxidase for Improvement of False Positive Error Caused by Bilirubin on Cholesterol Efflux Capacity Assay by Immobilize Liposome-Bound Gel Beads method

The Influence of Blood Collection Tubes on Measurement of Cardiac Biomarkers.

The analytical performance assessment and clinical practice of three sensitive cardiac troponin Ⅰ assays

High-Performance Liquid Chromatographic Determination of Creatine Kinase Activity Influenced by Methylglyoxal

Effect of exogenous lipids contamination on blood gas analysis

Reference Method Applied to Assigning Values for Calibrators in Serum Gamma-Glutamyltransferase Assays

Application of Five Frozen Human-Pooled Serum Samples Assigned by the International Federation of Clinical Chemistry and Laboratory Medicine Reference Procedure in a Traceability Investigation of Γ-Glutamyltransferase Catalytic Concentration Measurements in China

Application of magnetic bead method in detecting coagulation function

The analysis of cold agglutinins causing the error inspection result of blood analyzer

Investigation of precision and trueness of the glucose results from 15 measure systems in 4 domestic factories

Ensure the accuracy and consistency of biochemical analyzer test results: Chemometrics for instrument and inter-instrument item comparison in Chinese hospital laboratory

Application of reference methods suggested by IFCC and analysis of the 2006 ring trial results

Colloidal Gold Immunochromatography Assay for Cardiac Markers in the Diagnosis of Acute Myocardial Infarction

The influence of M protein interference on the routine biochemical assays of serum samples